Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119


Anaplastic lymphoma kinase: signalling in development and disease.

Palmer RH, Vernersson E, Grabbe C, Hallberg B.

Biochem J. 2009 May 27;420(3):345-61. doi: 10.1042/BJ20090387. Review.


The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.

Kelleher FC, McDermott R.

Eur J Cancer. 2010 Sep;46(13):2357-68. doi: 10.1016/j.ejca.2010.04.006. Epub 2010 May 5. Review.


Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.

Werner MT, Zhao C, Zhang Q, Wasik MA.

Blood. 2017 Feb 16;129(7):823-831. doi: 10.1182/blood-2016-05-717793. Epub 2016 Nov 22. Review.


Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.

Li R, Morris SW.

Med Res Rev. 2008 May;28(3):372-412. Review.


Targeting anaplastic lymphoma kinase in lung cancer.

Shaw AT, Solomon B.

Clin Cancer Res. 2011 Apr 15;17(8):2081-6. doi: 10.1158/1078-0432.CCR-10-1591. Epub 2011 Feb 2. Review.


Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H.

Nature. 2007 Aug 2;448(7153):561-6. Epub 2007 Jul 11.


Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.

Riera L, Lasorsa E, Ambrogio C, Surrenti N, Voena C, Chiarle R.

J Biol Chem. 2010 Aug 20;285(34):26441-50. doi: 10.1074/jbc.M110.116327. Epub 2010 Jun 16.


Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.

Boland JM, Erdogan S, Vasmatzis G, Yang P, Tillmans LS, Johnson MR, Wang X, Peterson LM, Halling KC, Oliveira AM, Aubry MC, Yi ES.

Hum Pathol. 2009 Aug;40(8):1152-8. doi: 10.1016/j.humpath.2009.01.012. Epub 2009 Apr 22.


Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease.

Yee HT, Ponzoni M, Merson A, Goldstein M, Scarpa A, Chilosi M, Menestrina F, Pittaluga S, de Wolf-Peeters C, Shiota M, Mori S, Frizzera G, Inghirami G.

Blood. 1996 Feb 1;87(3):1081-8.


Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.

Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG.

Leukemia. 2000 Sep;14(9):1533-59. Review.


The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma.

Horie R, Watanabe M, Ishida T, Koiwa T, Aizawa S, Itoh K, Higashihara M, Kadin ME, Watanabe T.

Cancer Cell. 2004 Apr;5(4):353-64.


[Implications of ALK (anaplastic lymphoma kinase) in oncohematology].

Cluzeau T, P├ęcuchet N, Mounier N, Vignot S.

Bull Cancer. 2010 Aug;97(8):991-6. doi: 10.1684/bdc.2010.1122. Review. French.


CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.

Cheng M, Quail MR, Gingrich DE, Ott GR, Lu L, Wan W, Albom MS, Angeles TS, Aimone LD, Cristofani F, Machiorlatti R, Abele C, Ator MA, Dorsey BD, Inghirami G, Ruggeri BA.

Mol Cancer Ther. 2012 Mar;11(3):670-9. doi: 10.1158/1535-7163.MCT-11-0776. Epub 2011 Dec 27.


Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.

Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, Pandita A, Tang J, Modrusan Z.

Mol Cancer Res. 2009 Sep;7(9):1466-76. doi: 10.1158/1541-7786.MCR-08-0522. Epub 2009 Sep 8.

Supplemental Content

Support Center